Immunity to Hepatitis-A virus: A nationwide population-based seroprevalence study from Iran |
| |
| Institution: | 1. Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran;2. MD/MPH Program, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran;3. Non Communicable Disease Research Center, Fasa University of Medical Sciences, Fasa, Iran;4. Center for Communicable Disease Control, Ministry of Health and Medical Education, Tehran, Iran;5. Modeling in Health Research Center, Kerman University of Medical Sciences, Kerman, Iran;6. Center for Disease Control, Shiraz University of Medical Sciences, Shiraz, Iran;7. Department of Community and Preventive Medicine, Fasa University of Medical Sciences, Fasa, Iran;8. Department of Epidemiology, Shiraz University of Medical Sciences, Shiraz, Iran;9. Department of Internal Medicine, Gastroenterology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran;10. Burn and Wound Healing Research Center, Microbiology Department, Shiraz University of Medical Sciences, Shiraz, Iran;1. Department of Microbiology, Harbin Medical University, Harbin, China;2. Department of National Immunization Program, China Center for Disease Control and Prevention, Beijing 100050, China;1. Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing 100193, China;2. Key Laboratory of Animal Epidemiology of the Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China;1. Laboratorio Central, Ministerio de Salud de la Provincia de Córdoba, Argentina;2. Instituto de Virología “Dr. J.M.Vanella”, Facultad de Ciencias Médicas, CONICET, Universidad Nacional de Córdoba, Argentina;3. Area Epidemiología, Ministerio de Salud de la Provincia de Córdoba, Argentina;1. Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran;2. Hyrcania Cancer Research Center, Golestan University of Medical Sciences, Gorgan, Iran;3. Deputy of Public Health, Golestan University of Medical Sciences, Gorgan, Iran;4. Deputy of Research and Technology, Golestan University of Medical Sciences, Gorgan, Iran;5. Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran;6. Department of Pathology, Sayyad Shirazi Hospital, Golestan University of Medical Sciences, Gorgan, Iran;7. Death Registry Unit, Deputy of Public Health, Golestan University of Medical Sciences, Gorgan, Iran;8. Deputy of Treatment, Golestan University of Medical Sciences, Gorgan, Iran;9. Statistics and Information Technology Office, Golestan University of Medical Sciences, Gorgan, Iran;10. Shafa Radiotherapy Center, 5 Azar Hospital, Gorgan, Iran;11. Digestive Oncology Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran;12. Cancer Surveillance Section, International Agency for Research on Cancer, Lyon, France;1. Institute of Preventive Veterinary Medicine, Sichuan Agricultural University, Wenjiang, Chengdu City, Sichuan 611130, PR China;2. Key Laboratory of Animal Disease and Human Health of Sichuan Province, Sichuan Agricultural University, Wenjiang, Chengdu City, Sichuan 611130, PR China;3. Avian Disease Research Center, College of Veterinary Medicine, Sichuan Agricultural University, Wenjiang, Chengdu City, Sichuan 611130, PR China |
| |
| Abstract: | BackgroundThe mortality rate of acute Hepatitis A increases from 0.1% in the children to 1.2%, in the adults. Hepatitis A is efficiently prevented by HAV-vaccine, but the strategy for distributing this vaccine among countries is dependent on their level of immunity to HAV. This study aimed to detect the level of immunity to HAV in Iran.MethodsIn this population-based seroprevalence study, 5419 participants from 12 of provinces of Iran, including 57 urban and 120 rural areas were chosen through a multi-stage cluster random sampling. Participants were interviewed by filling checklists and 3 cc of blood sample was obtained from each of them. IBM SPSS statistics V.21 software was used for univariable and multivariable analysis of data.ResultsMean of age of Interviewees was 26.4 ± 16 years, ranging from 1 to 94 years with a male to female ratio 1.02. Overall, 3603 (66.5%) of subjects were seropositive for HAV-IgG. Among the age groups, 41.1% of children by the age 15 years and 82.6% of adults around 30 years old were immune to HAV. The Mid-point age of population immunity was 21 years. Residents of the borders of the country, people who had less access to the safe water or sanitary toilet, individuals with low socioeconomic status and persons who were a member of dense families had the most probability of seropositivity.ConclusionsThis study showed that Iran is among HAV low endemic countries and vaccination against HAV is recommended only in the high-risk population, including patients with chronic liver diseases, patients with coagulopathy, travelers to the high endemic areas, and homosexuals. Establishment of national HAV surveillance system, concerning of health system about the occurrence of the HAV outbreaks, implementation of harm reduction strategies, improving economic indices and sanitation and access to the safe water in the deprived regions is recommended. |
| |
| Keywords: | Hepatitis A virus Immunoglobulin G Immunity Vaccination Iran |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
